How Is a PSA Test Done and What Do Results Mean?

A PSA test is a simple blood draw from a vein in your arm, usually taking less than a minute, that measures the concentration of prostate-specific antigen circulating in your bloodstream. The result comes back as a number in nanograms per milliliter (ng/mL), and what that number means depends on your age, the size of your prostate, medications you take, and whether anything has recently irritated the gland. The test itself is straightforward, but interpreting the result is where things get complicated, because PSA is not a cancer-specific marker.

What PSA Actually Is

Prostate-specific antigen is a protein made almost exclusively by cells in the prostate gland. Its biological job has nothing to do with cancer detection. PSA is one of the main proteins in semen, where it breaks down clotting proteins called semenogelins to liquefy the seminal fluid after ejaculation.¹ A small amount of PSA leaks from the prostate into the bloodstream under normal conditions, and that tiny leak is what the blood test picks up. Anything that disrupts, inflames, or enlarges the prostate can increase the leak, which is why an elevated number does not automatically mean cancer.

How the Blood Draw Works

There is no special preparation required for most men, though your doctor may suggest avoiding ejaculation for a day or two before the test and scheduling the draw before a digital rectal exam rather than after. A nurse or phlebotomist ties an elastic band around your upper arm, cleans a spot on the inside of your elbow, and inserts a needle into a vein to collect a small tube of blood. The sample goes to a lab where an immunoassay measures the amount of PSA protein in the serum. Results typically come back within a few days. The entire process feels like any other routine blood test.

What the Numbers Mean

For years, the conventional cutoff was 4.0 ng/mL: anything below that was considered “normal” and anything above it triggered further investigation. That one-size-fits-all threshold is now outdated. Research has established that PSA levels rise naturally with age even in men without cancer, so age-adjusted reference ranges give a more accurate picture. A widely cited study found that the 95th-percentile upper limit for healthy men aged 40 to 49 was 2.5 ng/mL, rising to 3.5 for men in their 50s, 4.5 for men in their 60s, and 6.5 for men in their 70s.² Data from other populations confirms the age correlation, with median values climbing steadily from decade to decade.³

These ranges mean a PSA of 3.0 in a 45-year-old is more concerning than a PSA of 3.0 in a 72-year-old, even though both sit below the old blanket cutoff. Context matters more than the raw number.

Non-Cancerous Reasons PSA Goes Up

Elevated PSA alarms many men, but cancer is only one of several possible explanations. Two of the most common non-cancerous causes are benign prostatic hyperplasia (BPH, the age-related enlargement of the prostate that affects most older men) and prostatitis (inflammation or infection of the gland). In a study comparing men with high versus low PSA levels, the high-PSA group had substantially larger prostates and much more inflammation. Prostate size alone accounted for roughly a quarter of the variation in PSA levels, with inflammation adding another chunk on top of that.⁴ Even subclinical inflammation, meaning inflammation you would not notice symptom-wise, can push the number up.

Prostatitis is worth particular attention because it can cause dramatic spikes. In men undergoing prostate surgery for benign disease, PSA values strongly correlated with the extent of both acute and chronic-active inflammation found in the tissue.⁵ And in rare extreme cases, acute prostatitis combined with BPH has been documented pushing PSA into the hundreds or even above 1,000 ng/mL, a level that would initially look terrifying on a lab report but turned out to be entirely infection-driven.⁶ This is a good illustration of why a single elevated reading should never be treated as a definitive cancer diagnosis.

Temporary Factors That Can Bump Your PSA

Several everyday activities can temporarily raise PSA, which is why doctors sometimes repeat a test before jumping to conclusions. Ejaculation is the one most men have heard about. One screening-population study found the average change after ejaculation was not statistically meaningful, and that PSA levels returned to baseline within about 12 hours.⁷ Other research, though, has shown that at the one-hour mark after ejaculation, the majority of men in screening-age groups had a measurable rise in total PSA, with the effect fading over the following day.⁸ The practical upshot: abstaining for 24 to 48 hours before a PSA draw is a reasonable precaution, though the impact is usually small.

Vigorous cycling is another commonly cited trigger. Long-distance riding applies sustained pressure to the perineum, which sits right over the prostate, and research has documented PSA rises in men over 50 after extended rides.⁸ Digital rectal exams and catheterizations can cause similar short-lived bumps. If your PSA comes back borderline and you recently did anything that physically compressed the prostate, your doctor will likely suggest retesting after a waiting period rather than immediately ordering further workup.

Medications That Change the Baseline

If you take finasteride or dutasteride, two drugs commonly prescribed for BPH or hair loss, your PSA reading will be artificially low. These medications, known as 5-alpha-reductase inhibitors, shrink the prostate by blocking the conversion of testosterone to a more potent form. A consistent finding across clinical trials is that finasteride cuts PSA by roughly half within the first year of use.⁹ After that initial drop, levels stabilize.¹⁰

This is important because it means a “normal-looking” PSA in someone on finasteride or dutasteride might actually be abnormal when you account for the drug’s suppressive effect. The standard clinical recommendation is to double the measured PSA value for men who have been on one of these drugs for at least a year to get a truer estimate.¹¹ If you are taking either medication, make sure your doctor knows before interpreting any PSA result.

Free-to-Total PSA Ratio and Other Refinements

When a total PSA result lands in the “gray zone” between roughly 2 and 10 ng/mL, neither clearly normal nor dramatically elevated, doctors often look at more detailed breakdowns. PSA circulates in two forms: “free” PSA (floating unbound in the blood) and “complexed” PSA (attached to other proteins). Cancer tends to produce more of the complexed form, so a lower percentage of free PSA relative to total PSA raises suspicion. Studies have shown that the free-to-total ratio significantly improves the ability to distinguish BPH from cancer compared to total PSA alone, and can reduce the number of unnecessary biopsies.¹²¹³ A commonly used cutoff is a free-to-total ratio below about 15 to 16%, at which point sensitivity for cancer detection is reasonably high, though specificity remains imperfect.¹⁴

Another useful concept is PSA velocity, which tracks how quickly your PSA changes over time. A rapid annual rise, particularly more than 2.0 ng/mL per year, has been linked to a significantly shorter time to death from prostate cancer after treatment, suggesting the cancer is aggressive.¹⁵ This is why tracking your PSA over several years gives your doctor more useful information than any single measurement. A stable number that stays within your age-appropriate range is reassuring in a way that a one-off snapshot cannot be.

How Accurate Is PSA as a Cancer Test?

Here is the tension at the heart of PSA screening: the test is very good at catching cancer when it exists, but very poor at ruling out cancer when it does not. A large meta-analysis pooling data from more than 14,000 symptomatic patients found that PSA’s sensitivity for prostate cancer was about 93%, meaning it correctly flagged the vast majority of men who actually had cancer. But its specificity was only around 20%, meaning it incorrectly flagged the vast majority of men who did not have cancer.¹⁶ In other words, most men with an elevated PSA do not have prostate cancer. The test casts a wide net.

That poor specificity is the root of PSA screening’s biggest drawback: overdiagnosis. PSA screening has improved early detection, but it also identifies slow-growing tumors that would never have caused symptoms or shortened a man’s life. Treating those indolent cancers with surgery or radiation exposes men to real side effects, including urinary incontinence and erectile dysfunction, for no survival benefit.¹⁷ Balancing the test’s ability to catch dangerous cancers early against the harm of treating harmless ones is what makes screening guidelines so contentious.

Current Screening Recommendations

The U.S. Preventive Services Task Force, which issues widely followed screening guidelines, recommends that men aged 55 to 69 make the screening decision individually with their doctor after discussing the potential benefits and harms. The benefit is a small reduction in the chance of dying from prostate cancer. The harms include false-positive results requiring further testing, overdiagnosis, overtreatment, and the side effects that come with treatment. The task force recommends against screening men over 70.¹⁸

Not all professional bodies agree on the details. The American Urological Association, the European Association of Urology, and the USPSTF differ on when to start screening, how often to repeat it, and how aggressively to pursue borderline results. What they all converge on is that blanket, one-threshold-fits-all screening is outdated, and that the conversation between you and your doctor, factoring in your personal risk profile, values, and preferences, is more important than any single number on a lab slip.¹⁹

What Happens After an Elevated Result

An elevated PSA does not mean you are immediately headed for a biopsy. The first step is usually to repeat the test after a few weeks to confirm the result. If it stays elevated, the next tier of investigation increasingly involves multiparametric MRI of the prostate. MRI can identify suspicious lesions that systematic needle biopsy might miss, and it helps target the biopsy to the most concerning areas.²⁰ A large trial found that using MRI to guide targeted biopsy, rather than performing routine systematic biopsy on everyone with an elevated PSA, could improve the detection of clinically meaningful cancers while reducing unnecessary tissue sampling.²¹

Alongside imaging, newer blood and urine biomarkers are filling the gap between a crude PSA number and a biopsy decision. The 4Kscore test combines several PSA-related measurements into a single risk percentage for aggressive cancer, helping men with borderline results decide whether a biopsy is warranted or safely deferrable.²² The Prostate Health Index (PHI) is another commercially available option that outperforms total PSA in predicting high-grade disease. On the urine side, PCA3 is a marker collected after a digital rectal exam that adds information particularly when a prior biopsy was negative.²³ None of these tests replace a biopsy for definitive diagnosis, but they give you and your doctor better tools to decide whether a biopsy is truly needed.

PSA Monitoring After a Cancer Diagnosis

Once prostate cancer is found, PSA takes on a different role: tracking the disease over time. For men with low-risk prostate cancer who choose active surveillance instead of immediate treatment, regular PSA testing is a cornerstone of the monitoring protocol. The PRIAS study, one of the largest prospective active-surveillance programs, followed men with regular PSA tests, digital rectal exams, and repeat biopsies. Over a decade of data, the investigators found that a fast-rising PSA should prompt further investigation but should not by itself trigger a switch to surgery or radiation. What actually mattered more was whether repeat biopsy showed the cancer’s grade worsening.²⁴

Other large surveillance cohorts follow a similar structure: PSA drawn every six months, rectal exams at the same interval, and periodic biopsies supplemented with MRI imaging.²⁵ For men who have undergone treatment rather than surveillance, PSA serves as a recurrence detector. After a radical prostatectomy, PSA should drop to undetectable levels since the prostate has been removed. A subsequent rise signals that cancer cells remain somewhere in the body. After radiation therapy, the expected pattern is a gradual decline, and a sustained rise above the post-treatment low point triggers concern. In both scenarios, the trend over multiple readings matters more than any individual number.

Race, Family History, and Who Should Screen Earlier

Standard screening guidelines often focus on men aged 55 to 69, but certain groups face higher risk and may benefit from earlier conversations with a doctor. Black men develop prostate cancer at higher rates, are diagnosed at more advanced stages, and tend to have higher-grade tumors compared to other racial and ethnic groups.²⁶ A systematic review found that Black men carry a higher prostate cancer risk even after accounting for socioeconomic and environmental factors, though the precise contribution of genetics versus environment remains debated.²⁷

Family history is another strong risk factor. Men with a first-degree relative who had prostate cancer face increased risk, and this holds true even when initial imaging or biopsy comes back clean.²⁷ Interestingly, though, a baseline PSA level measured around age 45 may be a stronger predictor of future prostate cancer death than either race or family history alone. One analysis found that the 10% of men with the highest PSA at age 45 accounted for 44% of eventual prostate cancer deaths, a concentration of risk that far exceeded what race or family history captured.²⁸ This suggests that a single early-adult PSA measurement could help identify who needs closer monitoring going forward, regardless of demographic category.

Why Your PSA Can Vary Between Labs

One underappreciated wrinkle with PSA testing is that different laboratory instruments can return slightly different numbers from the same blood sample. Despite international efforts to standardize the assays, clinically meaningful discrepancies between platforms persist. A study comparing several major commercial PSA assay systems found relative differences exceeding 10% at certain concentration levels, with some platforms consistently reading higher or lower than others.²⁹ This matters most when your PSA sits near a decision threshold. If one lab’s instrument reads you at 3.8 and another would read the same sample at 4.2, you might or might not cross a cutoff that triggers further investigation, depending on where you got your blood drawn.

The practical lesson is consistency: if you are tracking PSA over time, try to use the same lab and the same assay platform for each draw. Comparing numbers across different labs or different assay systems introduces noise that can look like a meaningful change when it is really just measurement variability. Your doctor can note which assay your lab uses and flag any switches that might distort trend comparisons.

PSA’s Origins as a Forensic Tool

There is an odd footnote to PSA’s history that most men being screened never learn. The protein was first characterized not as a cancer marker but as a forensic tool. Because PSA is produced in such high concentrations in semen, early research explored its use for identifying seminal fluid in sexual-assault investigations. Its potential as a prostate cancer marker emerged later, after researchers noticed that blood levels rose in men with prostate disease.³⁰ PSA remains one of the standard forensic tests for semen detection to this day, a reminder that the same molecule can serve completely different roles in different contexts. Its path from crime-lab tool to one of the most widely ordered cancer screening tests in medicine was anything but straightforward.